Episode Details
Back to Episodes
Discussing axSpA: 52-week results from the Phase 3 BE MOBILE trials
Published 3 weeks, 6 days ago
Description
Join Dr Sofia Ramiro and Dr Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered whether men and women with axSpA respond differently to bimekizumab, using 52-week data from the BE MOBILE 1 and 2 trials, covering both non-radiographic and radiographic axSpA.